Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial

Edwards T, Omollo R, Khalil EAG, Yifru S, Musa B, Musa A, Wasunna M, Smith PG, Royce C, Ellis S, Balasegaram M, Hailu A. Trials 2011, doi:10.1186/1745-6215-12-66.

Summary: AmBisome® is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not been identified. An open-label, 2-arm, non-inferiority, multi-centre randomized controlled trial is being conducted to determine the optimal single-dose treatment with AmBisome®.

Click here to read the article / PDF